Eosinophils in the new millennium

Journal of Allergy and Clinical Immunology

Volumn 119, Issue 6, 2007, Pages 1321-1322

  Rothenberg, Marc E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Allergy; eosinophilia; eotaxin; IL 5

Indexed keywords

INTERLEUKIN 5;

APOPTOSIS; CELL COMMUNICATION; CELL MATURATION; CELL SURVIVAL; CELL TRANSPORT; EDITORIAL; EOSINOPHIL; PRIORITY JOURNAL;

ALLERGY AND IMMUNOLOGY; ANIMALS; EOSINOPHILS; HUMANS;

EID: 34249791782     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.03.035     Document Type: Editorial

References (25)

1. Rothenberg M.E., and Hogan S.P. The eosinophil. Annu Rev Immunol 24 (2006) 147-174
2. Wong C.K., Cheung P.F., Ip W.K., and Lam C.W. Intracellular signaling mechanisms regulating Toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol (2007) Mar 1 [epub ahead of print]
3. Yu C., Cantor A.B., Yang H., Browne C., Wells R.A., Fujiwara Y., et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 195 (2002) 1387-1395
4. Lee J.J., Dimina D., Macias M.P., Ochkur S.I., McGarry M.P., O'Neill K.R., et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305 (2004) 1773-1776
5. Humbles A.A., Lloyd C.M., McMillan S.J., Friend D.S., Xanthou G., McKenna E.E., et al. A critical role for eosinophils in allergic airways remodeling. Science 305 (2004) 1776-1779
6. Fulkerson P.C., Fischetti C.A., Mcbride M.L., Hassman L.M., Hogan S.P., and Rothenberg M.E. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A 103 (2006) 16418-16423
7. Pope S.M., Brandt E.B., Mishra A., Hogan S.P., Zimmermann N., Matthaei K.I., et al. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 108 (2001) 594-601
8. Zimmermann N., Hershey G.K., Foster P.S., and Rothenberg M.E. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 111 (2003) 227-243
9. Rothenberg M.E. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 113 (2004) 11-28
10. Pope S.M., Fulkerson P.C., Blanchard C., Akei H.S., Nikolaidis N.M., Zimmermann N., et al. Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. J Biol Chem 280 (2005) 13952-13961
11. Pope S.M., Zimmermann N., Stringer K.F., Karow M.L., and Rothenberg M.E. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol 175 (2005) 5341-5350
12. Fulkerson P.C., Fischetti C.A., and Rothenberg M.E. Eosinophils and CCR3 regulate IL-13-transgene-induced pulmonary remodeling. Am J Pathol 169 (2006) 2117-2126
13. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
14. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A., Postma D.S., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167 (2003) 1655-1659
15. Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112 (2003) 1029-1036
16. Plotz S.G., Simon H.U., Darsow U., Simon D., Vassina E., Yousefi S., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349 (2003) 2334-2339
17. Klion A.D., Law M.A., Noel P., Kim Y.J., Haverty T.P., and Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103 (2004) 2939-2941
18. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113 (2004) 115-119
19. Stein M.L., Collins M.H., Villanueva J.M., Kushner J.P., Putnam P.E., Buckmeier B.K., et al. Anti-interleukin-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118 (2006) 1312-1319
20. Rosenberg H.F., Phipps S., and Foster P.S. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 119 (2007) 1303-1310
21. Jacobsen E.A., Taranova A.G., Lee N.A., and Lee J.J. Eosinophils: singularly destructive effector cells or purveyors of immunoregulation?. J Allergy Clin Immunol 119 (2007) 1313-1320
22. Munitz A., and Levi-Schaffer F. Inhibitory receptors on eosinophils: a direct hit to the Achilles heel. J Allergy Clin Immunol 119 (2007) 1382-1387
23. Simon D., and Simon H.U. Eosinophilic disorders. J Allergy Clin Immunol 119 (2007) 1291-1300
24. Foley S.C., Prefontaine D., and Hamid Q. Role of eosinophils in airway remodeling. J Allergy Clin Immunol 119 (2007) 1563-1566
25. Swartz J.M., Dyer K.D., Cheever A.W., Ramalingam T., Pesnicak L., Domachowske J.B., et al. Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood 108 (2006) 2420-2427